## 506459894 01/21/2021

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6506668

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST

#### **CONVEYING PARTY DATA**

Name	Execution Date
WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT	01/08/2021

### **RECEIVING PARTY DATA**

Name: WELLSTAT IMMUNOTHERAPEUTICS, LLC		
Street Address:	14200 SHADY GROVE ROAD, SUITE 600	
City:	ROCKVILLE	
State/Country:	MARYLAND	
Postal Code:	20850	

#### **PROPERTY NUMBERS Total: 7**

Property Type	Number
Application Number:	12529177
Application Number:	60892395
Application Number:	60985024
PCT Number:	US2012036459
Application Number:	61482827
Application Number:	61497835
Application Number:	61568518

#### **CORRESPONDENCE DATA**

**Fax Number:** (202)942-5999

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 2029426989

**Email:** john.rynkiewicz@arnoldporter.com,

cassandra.urbany@arnoldporter.com

Correspondent Name: JOHN P. RYNKIEWICZ

Address Line 1: 601 MASSACHUSETTS AVE., NW

Address Line 2: IP DOCKETING

Address Line 4: WASHINGTON, D.C. 20001-3743

ATTORNEY DOCKET NUMBER:	1030786.00003
NAME OF SUBMITTER:	JOHN P. RYNKIEWICZ
SIGNATURE:	/John P. Rynkiewicz/

PATENT 506459894 REEL: 054978 FRAME: 0958

DATE SIGNED:	01/21/2021									
Total Attachments: 6	Total Attachments: 6									
source=08. ImmunoTherapeutics - White	e Oak Pat Release_(US_169042326_2)#page1.tif									
source=08. ImmunoTherapeutics - White	e Oak Pat Release_(US_169042326_2)#page2.tif									
source=08. ImmunoTherapeutics - White	e Oak Pat Release_(US_169042326_2)#page3.tif									
source=08. ImmunoTherapeutics - White	e Oak Pat Release_(US_169042326_2)#page4.tif									
source=08. ImmunoTherapeutics - White	e Oak Pat Release_(US_169042326_2)#page5.tif									
source=08. ImmunoTherapeutics - White	e Oak Pat Release_(US_169042326_2)#page6.tif									

#### TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT

This Termination and Release of Patent Security Agreement is made as of January 8, 2021, ("Release") by WHITE OAK GLOBAL ADVISORS, LLC, a Delaware limited liability company ("Administrative Agent") in favor of WELLSTAT IMMUNOTHERAPEUTICS, LLC, a Delaware limited liability company ("Grantor"). Capitalized terms used but not otherwise defined herein have the meanings given to them in the Patent Security Agreement.

**WHEREAS**, the Grantor and the Administrative Agent and the other parties thereto entered into that certain Loan Agreement, dated August 1, 2013.

**WHEREAS,** in connection with the Loan Agreement, the Grantor entered into a Patent Security Agreement, dated August 1, 2013, with the Administrative Agent, notice of which was recorded at the United States Patent and Trademark Office on August 15, 2013, at Reel 031030, Frames 0549 to 0559.

**WHEREAS,** under the Patent Security Agreement, the Grantor granted to the Administrative Agent a security interest and continuing lien on all of the Grantor's right, title and interest in, to and under the Patent Collateral.

**WHEREAS,** the Administrative Agent has agreed to terminate and release its security interest in all such Patent Collateral as herein provided.

**NOW, THEREFORE,** for good and valuable consideration, including the satisfaction of all obligations, indebtedness, and liabilities secured by Patent Collateral pursuant to the Patent Security Agreement and the Loan Agreement, the receipt and adequacy of which are hereby acknowledged and upon the terms set forth in this Release, the Administrative Agent agrees as follows:

Section 1. The Administrative Agent hereby terminates, releases and discharges its security interest in the Patent Collateral under the Patent Security Agreement, including without limitation (i) the Patents listed on **Schedule A** attached hereto, including all applications therefor; (ii) all reissues, divisions, continuations, continuations-in-part, extensions, renewals, and reexaminations thereof; (iii) all rights corresponding thereto throughout the world; (iv) all inventions and improvements described therein; (v) all rights to sue for past, present and future infringements thereof; (vi) all licenses, claims, damages, and proceeds of suit arising therefrom; and (vii) all proceeds, payments and rights to payments arising out of the sale, lease, license, assignment, or other disposition thereof. Any right, title or interest of the Administrative Agent in such Patent Collateral shall hereby cease and become void, and the Administrative Agent hereby reassigns any and all interest that it may have therein to the Grantor.

Section 2. The Administrative Agent hereby authorizes the filing of this Release in the United States Patent and Trademark Office by the Grantor or its designees.

<u>Section 3</u>. This Release may be executed and delivered by e-mail or other means of electronic transmission (including .pdf), and such transmission shall constitute an original for all purposes.

Section 4. This Release and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Release and the transactions contemplated hereby shall be governed by, and construed in accordance with, the laws of the United States and the State of New York, without giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction).

[Signature page follows.]

IN WITNESS WHEREOF, the Administrative Agent has caused this Release to be executed and delivered by its duly authorized officer as of the day and year first written above.

WHITE OAK GLOBAL ADVISORS, LLC, as Administrative Agent

By: Bataross MKen

Name: Barbara J. S. McKee Title: Managing Partner

# **SCHEDULE A**

(See attached page)

Thorsday, June 13, 2013 Master List Page: 1

Case Number: 21001

Title: TREATMENT OF DISEASES CHARACTERIZED BY

INFLAMMATION

Division: Wellstat ImmunoTherapeutics, LLC

Owner:

Disclosure Status: Filed

Disclosure Date:

Attorney(s): LJK

Country	Sub Case	Case Type	Status	Application Number	Filing Date	Patent Number	Issue Date	Expiration Date
Australia	PC	PCT	Pending	200822187	29-Feb-2008		***************************************	***************************************
Canada	PC	PCT	Pending	2,678,774	29-Feb-2008			
China	PC	PCT	Pending	2008800068172	29-Feb-2008			
European Patent Convention	PC	PCT	Pending	08731123.9	29-Feb-2008			
Hong Kong	PC	ORD	Pending	10105197.8	27-May-2010			
Israel	PC	PCT	Pending	200368	29-Feb-2008			
Japan	PC	PCT	Pending	2009-551874	29-Feb-2008			
Korea, Republic of	PC	PCT	Pending	2009-7020557	29-Feb-2008			
Mexico	PC	PCT	Pending	MX/a/2009/009200	29-Feb-2008			
New Zealand	PC	PCT	Granted	578873	29-Feb-2008	578873	07-May-2012	29-Feb-2028
Patent Cooperation Treaty	PC	ORD	Published	PCT/US08/055498	29-Feb-2008			
South Africa	PC	PCT	Pending	2009/05364	29-Feb-2008			
United States of America		ORD	Pending	12/529177	28-Aug-2009			
United States of America	P	PRO	Pending	60/892395	03-Mar-2007			03-Mar-2008
United States of America	<b>P</b> 1	PRO	Pending	60/985024	02-Nov-2007			02-Nov-2008

Thorsday, June 13, 2013 Master List Page: 2

Case Number: 21002

Title: Complement Factor B Analogs and Their Uses

**Division:** Wellstat ImmunoTherapeutics, LLC **Owner:** Wellstat ImmunoTherapeutics, LLC

**RECORDED: 01/21/2021** 

Disclosure Status: Filed
Disclosure Date:
Attorney(s): LJK

Country	Sub Case	Case Type	Status	Application Number	Filing Date	Patent Number	Issue Date	Expiration Date
Patent Cooperation Treaty	PC	ORD	Published	PCT/US2012/036459	14-May-2012			
United States of America	P	PRO	Pending	61/482827	05-May-2011			05-May-2012
United States of America	P2	PRO	Pending	61/497835	16-Jun-2011			16-Jun-2012
United States of America	Р3	PRO	Pending	61/568518	08-Dec-2011			08-Dec-2012